دورية أكاديمية
Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide.
| العنوان: | Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide. |
|---|---|
| المؤلفون: | Ridolo, Erminia, Pellicelli, Irene, Gritti, Bruna, Incorvaia, Cristoforo |
| المصدر: | Patient Preference & Adherence. Jan2019, Vol. 13, p145-150. 6p. |
| مصطلحات موضوعية: | *GLYCOPYRROLATE, *MUSCARINIC antagonists, *ADRENERGIC beta agonists, *PATIENT satisfaction, *MUSCARINIC agonists, *RANDOMIZED controlled trials, *SELF-confidence |
| مستخلص: | Dual bronchodilation with long-acting beta-2 agonists and muscarinic antagonists is recommended in patients with severe to very severe COPD. Among dual bronchodilator combinations, indacaterol/glycopyrronium combination (IGC) received evidence of higher efficacy and good safety compared with monotherapy with either drug as well as with tiotropium. In randomized controlled trials, the primary outcome is usually the change in mean FEV1 resulting from treatment. However, the functional aspects that influence the physician's choice of the type of management may not be considered important by the patient, based on his perception of the disease. To address such issue, patient-reported outcomes (PROs) were assessed in recent studies. They include patient's perception of breathlessness, physical functioning, global health status, quality of life, use of rescue medications, and patient's report of COPD exacerbations. PRO data from the studies showed a clear improvement in patients' awareness of a better control of the disease in patients treated with IGC. In addition, the latest literature on two important issues influencing patient's preference and adherence, ie, the once-daily administration and the device to be used, confirmed the effectiveness of IGC and the ability of its device (Breezhaler®) to result in patient's satisfaction, ease of use, less handling errors, and self-assurance to have inhaled the entire dose. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: | Academic Search Index |
Full Text Finder | ResultId |
1 |
|---|---|
| Header |
asx Academic Search Index 134450121 1269 6 Academic Journal academicJournal 1269.30883789063 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=asx&AN=134450121&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:asx&genre=article&issn=1177889X&ISBN=&volume=13&issue=&date=20190101&spage=145&pages=145-150&title=Patient Preference & Adherence&atitle=Patient-reported%20outcomes%20and%20considerations%20in%20the%20management%20of%20COPD%3A%20focus%20on%20indacaterol%2Fglycopyrronium%20bromide.&id=DOI:10.2147/PPA.S166704 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide.
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Ridolo%2C+Erminia%22">Ridolo, Erminia</searchLink><br /><searchLink fieldCode="AR" term="%22Pellicelli%2C+Irene%22">Pellicelli, Irene</searchLink><br /><searchLink fieldCode="AR" term="%22Gritti%2C+Bruna%22">Gritti, Bruna</searchLink><br /><searchLink fieldCode="AR" term="%22Incorvaia%2C+Cristoforo%22">Incorvaia, Cristoforo</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <searchLink fieldCode="JN" term="%22Patient+Preference+%26+Adherence%22">Patient Preference & Adherence</searchLink>. Jan2019, Vol. 13, p145-150. 6p. ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => *<searchLink fieldCode="DE" term="%22GLYCOPYRROLATE%22">GLYCOPYRROLATE</searchLink><br />*<searchLink fieldCode="DE" term="%22MUSCARINIC+antagonists%22">MUSCARINIC antagonists</searchLink><br />*<searchLink fieldCode="DE" term="%22ADRENERGIC+beta+agonists%22">ADRENERGIC beta agonists</searchLink><br />*<searchLink fieldCode="DE" term="%22PATIENT+satisfaction%22">PATIENT satisfaction</searchLink><br />*<searchLink fieldCode="DE" term="%22MUSCARINIC+agonists%22">MUSCARINIC agonists</searchLink><br />*<searchLink fieldCode="DE" term="%22RANDOMIZED+controlled+trials%22">RANDOMIZED controlled trials</searchLink><br />*<searchLink fieldCode="DE" term="%22SELF-confidence%22">SELF-confidence</searchLink> ) Array ( [Name] => Abstract [Label] => Abstract [Group] => Ab [Data] => Dual bronchodilation with long-acting beta-2 agonists and muscarinic antagonists is recommended in patients with severe to very severe COPD. Among dual bronchodilator combinations, indacaterol/glycopyrronium combination (IGC) received evidence of higher efficacy and good safety compared with monotherapy with either drug as well as with tiotropium. In randomized controlled trials, the primary outcome is usually the change in mean FEV1 resulting from treatment. However, the functional aspects that influence the physician's choice of the type of management may not be considered important by the patient, based on his perception of the disease. To address such issue, patient-reported outcomes (PROs) were assessed in recent studies. They include patient's perception of breathlessness, physical functioning, global health status, quality of life, use of rescue medications, and patient's report of COPD exacerbations. PRO data from the studies showed a clear improvement in patients' awareness of a better control of the disease in patients treated with IGC. In addition, the latest literature on two important issues influencing patient's preference and adherence, ie, the once-daily administration and the device to be used, confirmed the effectiveness of IGC and the ability of its device (Breezhaler®) to result in patient's satisfaction, ease of use, less handling errors, and self-assurance to have inhaled the entire dose. [ABSTRACT FROM AUTHOR] ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Identifiers] => Array
(
[0] => Array
(
[Type] => doi
[Value] => 10.2147/PPA.S166704
)
)
[Languages] => Array
(
[0] => Array
(
[Code] => eng
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 6
[StartPage] => 145
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => GLYCOPYRROLATE
[Type] => general
)
[1] => Array
(
[SubjectFull] => MUSCARINIC antagonists
[Type] => general
)
[2] => Array
(
[SubjectFull] => ADRENERGIC beta agonists
[Type] => general
)
[3] => Array
(
[SubjectFull] => PATIENT satisfaction
[Type] => general
)
[4] => Array
(
[SubjectFull] => MUSCARINIC agonists
[Type] => general
)
[5] => Array
(
[SubjectFull] => RANDOMIZED controlled trials
[Type] => general
)
[6] => Array
(
[SubjectFull] => SELF-confidence
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide.
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ridolo, Erminia
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Pellicelli, Irene
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Gritti, Bruna
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Incorvaia, Cristoforo
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Text] => Jan2019
[Type] => published
[Y] => 2019
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 1177889X
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 13
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Patient Preference & Adherence
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |